Precision Medicine With Ketamine for Older Adults With Treatment-resistant Depression: Pilot Study
Phase: PHASE4
Conditions: Treatment Resistant Depression, Refractory Depression, Therapy-Resistant Depression, Late Life Depression, Geriatric Depression
Sponsor: Washington University School of Medicine

Protocol Version: 4 
 
1 
Protocol Date: 10/12/21 
Precision medicine with ketamine for older adults 
with treatment-resistant depression: Pilot Study 
 
PI: Eric Lenze 
WUSTL IRB ID#: 202007085 
ClinicalTrials.Gov Identifier: NCT04504175 
 
 
 

Protocol Version: 4 
 
2 
Protocol Date: 10/12/21 
I. 
STUDY OVERVIEW 
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine in older adults with 
Treatment-Resistant Depression (TRD). In addition, this study will develop and utilize innovative 
methodological approaches to demonstrate the feasibility of precision medicine and mHealth approaches 
in depression treatment.  
II. 
METHODS 
A. 
Design Overview 
Participants will receive ketamine infusions twice a week for 4 weeks (acute phase). Participants who 
respond or remit will continue with an additional 4 weeks of weekly ketamine infusions (continuation 
phase). Participants will be assessed at baseline, end of acute phase, and end of continuation phase for 
effectiveness, safety, and executive functioning. Participants will be asked to complete daily surveys of 
their depression symptoms during their participation.   
B. 
Participant Recruitment 
The study will enroll up to 15 participants. Participants will be enrolled from existing studies (WU 
IRB#201609085, 201202157, and 201811036). In addition we will elicit referrals from our established 
referral networks of PCPs and specialty mental health practices. Potential participants will undergo pre-
screens by phone and then an in-person visit that includes a psychiatric and medical history, blood 
chemistries, and an ECG. 
1. 
Inclusion Criteria 
(1)  
Community-living men and women age 60 years and older;  
(2) 
Treatment-resistant depression: defined as unipolar major depressive disorder, non-delusional 
(diagnosed by SCID-5) that persists despite ≥ 2 adequate antidepressant trials of different classes in the 
current episode; including at least one evidence-based second-line treatment in the current episode 
(including serotonin norepinephrine reuptake inhibitors, bupropion, tricyclics, monoamine oxidase 
inhibitors, or augmentation with an atypical antipsychotic, stimulant, bupropion, lithium, or 
Triiodothyroinine 
(3) 
Persistent moderate to severe depressive symptoms determined by Patient Health Questionnaire 
9-item (PHQ-9)26 score ≥15 at baseline  
(4)  
Able to provide informed consent. 
2. 
Exclusion Criteria 
(1) 
Dementia per history, score ≥10  on the Short Blessed Test, or determined by clinical interview 
with geriatric psychiatrist to have high likelihood of dementia;  
(2)  
Psychotic spectrum or bipolar disorder or severe personality disorder that at the PIs discretion 
would interfere with safe participation.  Anxiety disorders are not an exclusion.  
(3)  
Unstable medical conditions such that IV ketamine is not safe or tolerated or that would interfere 
with participation in a long-term study (i.e., poorly controlled hypertension, life expectancy < 1 year 
because of terminal illness, unstable angina).  

Protocol Version: 4 
 
3 
Protocol Date: 10/12/21 
(4)  
Baseline systolic BP > 150 systolic or 90 diastolic at evaluation. Participants who initially present 
with elevated blood pressure may be re-assessed; and if needed, referred to their healthcare provider for 
hypertension management. Clonidine is preferred as the agent to control blood pressure, as it will also 
improve tolerability of ketamine infusion.  However, patients' providers are not required to use this drug 
(vs. other strategies such as optimizing doses of existing medication). Once blood pressure is adequately 
managed, they can be reconsidered for study participation.  
(5) 
Current alcohol or substance use disorder or lifetime recreational ketamine use or other 
dissociative agent (e.g., PCP).  
(6)  
Use of naltrexone, memantine, or any medication that could be considered contraindicated with 
ketamine. 
(7) 
Taking more than 2 adequately-dosed oral antidepressants. 
(8) 
High acute risk for suicide and unable to be managed safely in the clinical trial. 
 
C. 
Screening Procedures 
After providing informed consent, participants will be assessed for eligibility as follows: 
1) SCID-5: Meet criteria for unipolar Major Depressive Disorder, non-delusional, current. Rule out 
psychotic and bipolar disorder.  
2) AUDIT: Rule out current alcohol use disorder (past 3 months) 
3) DAST: Rule out current substance use disorder (past 3 months) 
4) PHQ-9: Score must be 15 or higher at baseline. 
5) Short Blessed Test: Score must 0-9 (excluded if score is 10 or higher).  
6) ATHF:  Must have 2 or more adequate antidepressant trials of different classes in the current 
episode 
7) Review of current medications: Must not be taking naltrexone memantine, or any medication that 
could be considered contraindicated with ketamine. Must not be taking more than two 
adequately-dosed oral antidepressant. Must be stable on antidepressant regimen for at least two 
weeks.  
8) Review of medical conditions: Must not have any medical conditions affecting IV ketamine safety 
or tolerability or that would interfere with participation in a long-term study. (i.e., life expectancy 
< 1 year because of terminal illness, unstable angina). Must not have inadequately controlled 
hypertension.  
D. 
Schedule of Measures 
 
SCHEDULE OF MEASURES 
FOLLOW – UP +++ 
 
BASELINE 
ACUTE END 
(WK 4)* 
CONTINUATION 
END (WK 8)** 
1 
MONTH 
2 
MONTH 
3 
MONTH 
Screening 
 
 
 
 
 
 
SCID-5+ 
X 
 
 
 
 
 
PHQ-9 
X 
 
 
X 
X 
X 
ATHF 
X 
 
 
 
 
 

Protocol Version: 4 
 
4 
Protocol Date: 10/12/21 
Short 
Blessed 
Test 
X 
 
 
 
 
 
Blood Pressure 
X 
 
 
 
 
 
AUDIT 
X 
 
 
 
 
 
DAST 
X 
 
 
 
 
 
CIRS-G 
X 
 
 
 
 
 
Outcomes 
 
 
 
 
 
 
MADRS 
X 
X 
X 
X 
X 
X 
Scale for Suicidal 
Ideation (SSI) 
X 
X 
X 
 
 
 
Psychological 
well-being (NIH 
Toolbox) 
X 
X 
X 
 
 
 
Cognitive Battery 
(NIH Toolbox) 
X 
X 
X 
 
 
 
Miro Health 
Cognitive Battery 
X 
X 
X 
 
 
 
Pittsburgh Sleep 
Quality Index 
(PSQI)++ 
X 
X 
X 
 
 
 
Safety 
 
 
 
 
 
 
AE Monitoring 
X 
X 
X 
 
 
 
Medication List 
X 
X 
X 
 
 
 
Medical History 
X 
 
 
 
 
 
Height/Weight 
X 
 
weight 
 
 
 
ECG 
X 
 
X 
 
 
 
Blood 
Chemistries*** 
X 
 
X 
 
 
 
Craving Scale 
X 
X 
X 
 
 
 
Depression daily 
self-reports 
THROUGHOUT 
 
 
 
*Acute End assessments will take place after at least 4 weeks of treatment or upon early termination from 
Acute phase. There may be some delays between baseline assessments and the start of treatment.  
**Continuation End assessments will take place after the 8th week of treatment or upon early termination 
from Continuation phase.  
*** Blood chemistries may include CBC, BMP (including LFTs); and TSH at baseline if not obtained within 
the last 6 months.  
+Subset of SCID-5 will be administered to assess Bipolar And Related Disorders, Depressive Disorders, 
Schizophrenia And Other Psychotic Disorders 
++Item 6 of PSQI will be administered.  
+++ Follow-Up assessments (typically phone) will be conducted for participants who begin Continuation 
Phase at 1, 2, and 3 months after their last study visit (Wk 8, or their last study visit if the participant ends 
early) 

Protocol Version: 4 
 
5 
Protocol Date: 10/12/21 
E. 
Determination of Remission  
1. 
Acute Phase End 
Participants who complete the acute phase and reach a MADRS score indicating remission (<10) or  
response (30% reduction) will continue IV ketamine for  4 weeks. This continuation phase is needed to 
establish the stability of remission/response. 
Participants without a 30% reduction in  MADRS score at the end of the acute phase will not proceed to 
the Continuation Phase of the study; their participation will end. 
If needed, a 9th infusion can take place if there is an interruption of infusions during the final week of 
acute, give one additional so that in the final week prior to assessing response there have been 2 infusions. 
2. 
Continuation Phase End 
Participants who complete the Continuation phase will be assessed for remission and response using the 
MADRS. A second confirmatory MADRS will be obtained at the end of the Continuation Phase to 
determine final remission status.  
F. 
Intervention: Ketamine Infusions 
1. 
Details of Infusion 
To ensure dose accuracy, participants will have weight confirmed prior to each infusion. After safety 
ratings (see table below) are performed, an IV line will be inserted into upper extremity by research 
personnel. The ketamine will be infused using an IV infusion pump at a rate of 0.5 mg/kg of body weight 
over 40 minutes. Heartrate, blood pressure, and pulse-oximetry will be routinely monitored throughout 
the infusion and for approximately up to two hours after the end of the infusion. Safety ratings will be 
repeated prior to discharge. After normalization of any psychotomimetic symptoms or blood pressure 
elevation and IV removal, participants will be discharged. Participants will be provided with 
transportation to and from infusion visits. 
If a participant is unable to receive IV ketamine (e.g., because of lack of IV access), he or she can receive 
IM ketamine as a bolus. The dosage will be the same (0.5 mg/kg) because its bioavailability is 93% and 
its plasma half-life is similar to IV. 
2. 
Clonidine co-administration 
The two most concerning problems observed during infusions are sympathomimetic (blood pressure 
changes) and psychotomimetic/dissociation. These are a tolerability issue (patients may not tolerate 
ketamine secondary to these problems), safety issue (transient hypertension or psychosis require 
additional monitoring and could cause cardiac or psychiatric risks, although to date these have not been 
seen in our or others’ research), and an access issue (hypertension is common in older adults with 
depression and could prevent many patients from receiving an otherwise effective treatment).  Our 
group showed that co-administered clonidine, an alpha-2 agonist, safely and effectively mitigates both 
of these concerning side effects of ketamine. Thus, pre-dosing of clonidine can improve the tolerability 
of ketamine and maximize its potential treatment benefits. Clonidine has not been widely used in 
ketamine treatment of depression, but it is routinely co-administered with ketamine in chronic pain 
management to reduce these side effects, and perioperatively as well. Clonidine co-administration does 
not alter the antidepressant activity of ketamine in either preclinical or clinical studies. If indicated (see 
human subjects section) participants may receive a 0.1 mg oral clonidine test dose to ensure tolerability, 
and those who tolerate and accept it will receive pre-dosing with clonidine prior to infusions during the 

Protocol Version: 4 
 
6 
Protocol Date: 10/12/21 
acute phase.  Higher doses of clonidine (up to 0.3 mg) can be used if needed in certain cases to provide 
greater blood pressure control or prevent distressing neuropsychiatric symptoms (eg, dissociation).  The 
co-administration of clonidine does not introduce excess polypharmacy for older adults because it is 
used only on days of ketamine infusions, as needed. It may not be needed long-term for most patients, 
as ketamine’s neuropsychiatric side effects decline in most patients with repeat infusions.   
 
 
 
INFUSION SCHEDULE  
To accommodate delays in the infusion schedule for various reasons (e.g. participant 
travel, illness, or COVID-19 safety guidelines), each phase may be extended by an 
additional 4 weeks. 
Acute Phase 
Infusion Schedule 
Two infusions per week X 4 weeks (at least two days apart) 
Continuation Phase 
Infusion Schedule 
One infusion per week X 4 weeks 
 
Safety Monitoring for Infusions  
 
Before 
Infusion 
40 
Minutes 
After 
60 
Minutes 
After 
90 
Minutes 
After 
Weight 
X 
X 
X 
X 
Vital Signs: Blood Pressure, Pulse rate, oxygen 
saturation, body temperature 
X 
X 
X 
X 
Brief Psychiatric Rating Scale - positive (psychotic) 
symptom subscale (BPRS+) 
X 
X 
- 
X 
Clinician Administered Dissociative States Scale 
(CADSS) 
X 
X 
- 
X 
 
G. 
Potential Risks & Risk Mitigation 
Interviews/Questionnaires/Surveys: 
Participants may experience emotional discomfort with the neuropsychological testing and medical and 
psychological questionnaires. If any particular question makes the participant uncomfortable, the 
participant may discuss its importance and the need to answer it with the specially-trained interviewer. 
These assessments will be administered in private settings.  Participants have the right to refuse to answer 
any question for any reason.   
 
Infusion Procedure/Blood Draws/ Injections:  
While rare, participants may experience pain, bruising, and/or bleeding at the site of needle insertion for 
blood draws, injections and the intravenous catheter. There is a rare risk of infection from a needle 
insertion.  Phlebotomy, IM injection, and IV insertion will be performed by certified and trained staff. 
 
Ketamine: 

Protocol Version: 4 
 
7 
Protocol Date: 10/12/21 
Common side effects: Feeling light-headed, “high,” exhilarated, having perceptual changes or 
hallucinations, floating sensations, and/or difficulty concentrating, paying attention, or remembering as 
many items as usual from a list (like items on a grocery list)   Mild and temporary increases in blood 
pressure. 
Less likely: Feeling dizzy, sleepy, anxious, suspicious, nauseated.  
Rare side effects: Feeling sad, scared, confused, disoriented, moderate and temporary increases in blood 
pressure, future abuse of ketamine, prolonged psychosis in individuals with a pre-existing psychiatric 
condition. It is possible that the use of ketamine could increase interest in the illicit use or abuse of this 
substance although the fact that individuals with any past or current substance abuse will be excluded 
makes this highly unlikely.   
 
We will minimize these risks by adhering to all entry criteria, not enrolling participants with uncontrolled 
hypertension or other unstable medication conditions, having same-room observation of all participants 
during the infusion and for 2 hours post-infusion that includes blood pressure monitoring, oxygen 
saturation monitoring, and management of psychotomimetic adverse effects by highly trained and 
psychologically-informed nursing and medical support staff.  We will also use clonidine as needed the day 
of infusion (if determined to not increase risk of hypotension or orthostasis; see below). 
 
Plans to ensure cardiovascular safety during the ketamine infusions: The most frequent cardiovascular 
effect of ketamine infusion is increase in blood pressure. A study of 66 patients, mean age 57, 38% with 
controlled hypertension and excluding patients with either a systolic BP >160 mmHg or diastolic BP > 100 
mmHg at baseline, reported blood pressure effects of 684 IV ketamine infusions (Riva-Posse et al, Blood 
pressure safety of subanesthetic ketamine for depression: a report on 684 infusions. J Affect Disord 2018). 
In 9% of infusions a blood pressure measurement that was greater than 30 mmHg systolic or 15mmHg 
diastolic was recorded although there was no measurement that was greater than 45mmHg systolic of 
30mmHG diastolic over baseline.  The blood pressure increases were transitory. No patient required an 
intervention to treat blood pressure. 
In this study the mean age of the patient group is anticipated to be 10-13 years older than the patient 
group in the Riva-Posse study and it is also anticipated that the rate of controlled hypertension will be 
higher. There are several procedures to increase safety in this study. 
1. Participants with uncontrolled hypertension, defined as baseline systolic BP > 150 systolic or 90 
diastolic, will be excluded. 
2. Participants will be routinely pre-treated with clonidine 0.1mg the night before treatment and 
the morning of treatment, unless otherwise indicated (e.g., baseline BP is below 110 systolic of 
70 diastolic).  
3. Prior to each infusion BP will be measured after the patient has been lying quietly for 5 minutes. 
This recording will be the baseline BP. If baseline BP is elevated (Systolic > 160 or Diastolic >95), 
oral clonidine 0.1 mg will be administered and BP will be re-checked 20-30 minutes later. The 
dose of clonidine may be increased up to 0.2-0.3 mg depending upon participant benefit and 
tolerability. If BP continues to be elevated (Systolic > 160 or Diastolic >95), ketamine infusion 
will not be administered that day.  
4. During the IV ketamine infusion BP is recorded every 10 minutes. A measurement that shows a 
BP increase over 25% from systolic or diastolic baseline and reaches a level of 175 systolic or 105 
diastolic will trigger a repeat measurement in two minutes. If the same increase is recorded, 
then oral clonidine 0.1 mg will be given. If increased blood pressure measurements persist 
(above 175 systolic or 105 diastolic) the infusion will be discontinued. 

Protocol Version: 4 
 
8 
Protocol Date: 10/12/21 
5. If BP increases to levels described in #3 or participants experience psychotomimetic/dissociative 
effects, prior to the subsequent ketamine infusion, oral clonidine 0.1 mg will be taken by 
participants the night before the infusion and at least 30 minutes prior to the infusion.  The dose 
of clonidine may be increased up to 0.2-0.3 mg, depending upon participant benefit and 
tolerability, for a maximum total daily dose of 0.6 mg when clonidine is used by the team for 
pre-treatment (night before/morning of). (Lenze et al, Ninety-six hour ketamine infusion with 
co-administered clonidine for treatment-resistant depression; World J Biol Psychiatry 2016). 
6. An ECG will be done at baseline, at the end of continuation and at the end of the maintenance 
or at time of reoccurrence of depression 
 
Plans to monitor and minimize psychotomimetic/dissociative effects:   
We will measure transient neuropsychiatric changes with the Brief Psychiatric Rating Scale - positive 
(psychotic) symptom subscale (BPRS+) and the Clinician Administered Dissociative States Scale (CADSS) at 
baseline, 40 minutes, and 1.5 hours after infusion.  Patient participants must be asymptomatic according 
to these measures and to clinical assessment prior to discharge from the infusion center.  To prevent 
distressing symptoms, clonidine will be prescribed (see above) to take orally the night before and the 
morning of the subsequent infusion (dose starting at 0.1 mg, increased up to 0.3 mg as needed and 
tolerated).  Nursing and medical support staff will all be trained in the care of patient participants 
experiencing psychological symptoms in response to a medical treatment, and we will follow best practice 
nursing approaches to calm and comfort participants by re-orienting them, preventing wandering and 
falls, assuring them they are safe and their feelings are normal and transient, and by having a psychiatrist 
on call at all times.   
 
Clonidine: 
Common side effects: Dry mouth, constipation, nausea, vomiting, mild abnormalities in liver function 
blood tests; salivary gland pain, leg cramps pain or musculoskeletal pain or joint pain, and feeling weak. 
Less likely side effects: Dry throat, low blood pressure, dizziness, tremor; feeling nervous or irritable, 
having trouble sleeping or feeling drowsy, tired, or sedated; dry or blurred eyes or feeling tearful. 
Rare side effects: Lack of appetite, transient elevation of blood glucose or blood serum creatinine tests, 
fluid retention, sexual dysfunction, genitourinary effects, headache, abdominal pain, change in taste, 
unpleasant dreams, ECG abnormalities, and palpitations have also been reported. We will only use 
clonidine in participants who experience infusion-related blood pressure elevations or psychotomimetic 
effects (e.g., dissociation).  Prior to using low-dose clonidine, frequently prescribed for older adults with 
hypertension, and which we observed to be well-tolerated when administered prior to ketamine infusions 
to minimize these adverse effects, we will assure there are no pharmacodynamic interactions which would 
preclude its safe use, and as needed, consult with the participant’s primary care physician or the study’s 
PCP consultant, Dr. Bruce Rollman. 
 
Suicide:  
Patients who are identified as acutely suicidal will be excluded from the study and referred for acute 
psychiatric evaluation and care. Nevertheless, since the rate of completed suicide in the USA remains high 
(i.e., about twice the rate of homicide) and most Americans who commit suicide suffer from depression, 
all participants eligible to participate in this study are statistically at a relatively higher risk for suicide than 
the general population. However, the participants’ absolute risk for completing suicide during this study 
remains very low (i.e., about 1 in 3,000 to 10,000) and participation in the study does not create or 
increase the risk of completed suicide. Actually, most experts believe that one of the most efficient ways 
to decrease suicidal risk in older depressed individuals is to treat their depression. Furthermore, all 

Protocol Version: 4 
 
9 
Protocol Date: 10/12/21 
participants will be formally assessed at least every two weeks for the duration of the study, and we will 
make efforts to engage family caregivers and obtain an emergency phone number for all participants. All 
sites have a 24/7/365 on-call system with geriatric psychiatry back-up. If the study personnel identify that 
a participant has become acutely suicidal, the local study team will take all necessary efforts to assure the 
participant is safe (i.e., escort them to the emergency room for evaluation, activate emergency medical 
services, speak with PCP or family members). This may lead to a clinical intervention that is lifesaving and 
may not have occurred had the participant not been participating in the study.  We have published about 
our suicide safety risk management protocol (Herbeck Belnap et al, Electronic protocol for suicide risk 
management in research participants, J Psychosom Res 2015) and will follow this algorithm at every 
clinical assessment if it is triggered. This protocol has already been used successfully by this team to 
manage acutely suicidal patients in the ongoing OPTIMUM study. Briefly, the protocol entails a specific 
determination of the suicidal risk and prescribes a set of actions.  For instance, when a participant is 
determined to be at high and immediate risk, the rater is instructed to stay with the participant until he 
or she has contacted a clinician to discuss the situation and to devise a plan. For this reason, raters will 
have cell phones and a study clinician will be reachable via cell phone.  In case of extreme emergency, 
raters are instructed to call their hospital security team or 911 for immediate help and in order to have 
the participant escorted to the emergency department for further safety evaluation.   
Breach of Confidentiality: 
One risk of participating in this study is that confidential information may be accidentally disclosed.  We 
will follow our established best-practice procedures to keep the information about participants secure.  
All private information is stored in secured areas and on encrypted and password-protected servers. 
 
Other risks: 
Participants may experience all or some of the risks listed above.  There may also be unknown risks.  We 
will adjust the informed consent process if new risks are identified.  We will monitor adverse events and 
serious adverse events to determine if an emerging pattern suggests a re-evaluation of the risk/benefit 
ratio. 
 
III. 
SAFETY AND ADVERSE EVENTS  
A. 
Safety Monitoring 
Safety will be systematically monitored during infusions according to the Safety Monitoring for Infusions 
schedule.  
In addition, we will ask each participant to notify us of new symptoms, illnesses, or other problems.  
B. 
Definitions of Adverse Events 
An Adverse Event (AE) is any untoward medical occurrence in a subject or clinical investigation subject 
administered a drug under study.  An AE does not necessarily have a causal relationship with the study 
drug.   
The criteria for identifying AEs are: 
 
Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporally associated with the use of a drug under study, whether or not considered 
related to the drug under study 
 
Any new disease or exacerbation of an existing disease 

Protocol Version: 4 
 
10 
Protocol Date: 10/12/21 
 
Any deterioration in nonprotocol required measurements of a laboratory value or other clinical 
test (e.g., ECG or x ray) that results in symptoms, a change in treatment, or discontinuation of 
study drug 
 
Recurrence of an intermittent medical condition (e.g., headache) not present pretreatment (i.e., 
baseline) 
 
An abnormal laboratory test result should be considered an AE if the identified laboratory 
abnormality leads to any type of intervention, whether prescribed in the protocol or not. 
 
A laboratory result should be considered by the investigator to be an AE if it: 
o Results in the withdrawal of study drug 
o Results in withholding of study drug pending some investigational outcome 
o Results in an intervention, based on medical evaluation (e.g., potassium supplement for 
hypokalemia) 
o Results in any out of range laboratory value that in the investigator’s judgment fulfills 
the definitions of an AE with regard to the subject’s medical profile. 
 
All AEs observed during the study will be reported on the Redcap AE form.  All AEs, regardless of 
relationship to study drug or procedure, should be collected beginning from the time the subject signs the 
study ICF through the last visit.   
Abnormal laboratory values should not be listed as separate AEs if they are considered to be part of the 
clinical syndrome that is being reported as an AE.  Any laboratory abnormality considered to constitute 
an AE should be reported as an AE on the E-CRF. 
It is the responsibility of the investigator to review all laboratory findings in all subjects and determine if 
they constitute an AE.  Medical and scientific judgment should be exercised in deciding whether an 
isolated laboratory abnormality should be classified as an AE. 
C. 
Classification of Events 
Every effort must be made by the investigator to categorize each AE according to its severity and its 
relationship to the study treatment. 
1. 
Assessing Severity of Adverse Events  
AEs will be graded on a 3 point scale (i.e., mild, moderate, and severe) and reported in the detail indicated 
on the CRF.  The definitions are as follows: 
 
Mild: 
 
Discomfort noticed, but no disruption of normal daily activity 
 
Moderate: 
Discomfort sufficient to reduce or affect normal daily activity 
 
Severe:  
Incapacitating, with inability to work or to perform normal daily activity 
2. 
Assessing Relationship of Adverse Events 
The causal relationship of the study drug to an AE will be assessed as related or unrelated, as follows: 
 
Probably Related: 
There is a reasonable causal relationship between the study drug and 
the AE.  The event responds to dechallenge.  Seeing a recurrence of the AE with study 
medication rechallenge is not required. 
o Example: patient receives a ketamine infusion.  They report vertigo that starts during 
their infusion and persists for 2 days afterwards, interfering with their day-time 
functioning (moderate AE).  At the next infusion, the vertigo occurs again. 

Protocol Version: 4 
 
11 
Protocol Date: 10/12/21 
 
Possibly Related: 
There is a reasonable causal relationship between the study drug and 
the AE.   Dechallenge is lacking or unclear. 
o Example: patient reports new-onset insomnia the night after their first infusion but does 
not disrupt their daily activity (mild AE).  They continue with the infusions and insomnia 
does not reliably occur after subsequent infusions. 
Unrelated: 
 
Not Likely Related: 
There is a temporal relationship to study drug administration, but there 
is not a reasonable causal relationship between the study drug and the event. 
o Example: patient is started on ketamine infusions.  One day after the first infusion, they 
are driving and are hit by another car, necessitating hospitalization (severe and serious 
AE).  The accident is the fault of the other driver. 
3. 
Assessing Expectedness of Adverse Events  
An Unexpected Adverse Event is an adverse reaction, the nature or severity of which is not consistent 
with the applicable product information. 
4. 
Assessing Seriousness of Adverse Events 
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: 
• 
Results in death 
• 
Is life-threatening (i.e., the subject was at immediate risk of death from the adverse event 
as it occurred; this does not include an event that, had it occurred in a more severe form or was 
allowed to continue, might have caused death) 
• 
Requires inpatient hospitalization or prolongation of existing hospitalization 
• 
Results in persistent or significant disability or incapacity 
• 
Is a congenital anomaly or birth defect in the child of a subject who was exposed to the 
study drug 
Other important medical events that may not be immediately life threatening or result in death or 
hospitalization but, when based on appropriate medical judgment, may jeopardize the subject or may 
require intervention to prevent one of the outcomes in the definition of SAE listed above should also be 
considered SAEs.  Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is appropriate in such situations. 
The following hospitalizations are not considered to be SAEs because there is no “adverse event” (i.e., 
there is no untoward medical occurrence) associated with the hospitalization: 
• 
Hospitalizations for respite care 
• 
Hospitalization planned before informed consent where the condition requiring the 
hospitalization has not changed post study drug administration 
• 
Hospitalization for routine maintenance of a device (e.g., battery replacement) that was 
in place before study entry 

Protocol Version: 4 
 
12 
Protocol Date: 10/12/21 
D. 
Data Collection Procedures for Adverse Events 
Participating sites are responsible for gathering and documenting data pertinent to Adverse Events 
occurring at their sites and for collecting Adverse Event information from each treating physician, 
including but not limited to:  
 
Description of the event, including onset and duration 
 
Treatment assignment, dose recommendation, and adherence 
 
Relevant medical and laboratory findings and reports 
 
Correspondence regarding the event 
 
Action taken in response to the event 
 
Classification of the Adverse Event (Severity, Relationship, Expectedness, Seriousness) 
 
All Adverse Events observed during the study will be recorded on the Redcap AE form.  All Adverse Events 
will be collected from the time of informed consent through the last assessment.  
1.a 
Reporting Procedures for Adverse Events 
 
Serious Adverse Events: Must be reported to local site IRB as per each institutional policy.  
 
All Adverse Events: Document promptly via Redcap AE form, within 5 working days of the 
occurrence of the event or notification to the investigator or research team of the event.  
 
Other Reporting Requirements: Adverse Events will be reported per relevant reporting criteria 
and timeframes to IRB and FDA as required by each institutional policy.  
 
E. 
Data Management & Analysis 
The study is a pilot, feasibility study in that sample size is determined by feasibility, not a power 
calculation. If the study demonstrates feasibility of methods and a positive signal, then pilot data would 
be used to construct a larger, adequately-powered clinical trial with federal funding. 
Study data are collected and managed using REDCap electronic data capture tools hosted in the 
Washington University School of Medicine Institute for Informatics (I2), Informatics Core Services (ICS).  
REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data 
capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails 
for tracking data manipulation and export procedures; 3) automated export procedures for seamless 
data downloads to common statistical packages; and 4) procedures for importing data from external 
sources. 
Study data will also be collected using NIH Toolbox and Miro Health ipad applications which use 
recognized security features. Study devices will be kept secured and passcode-protected.  
  
IV. 
REFERENCES 
1. 
Lenze EJ, Rogers JC, Martire LM, et al. The association of late-life depression and anxiety with 
physical disability: a review of the literature and prospectus for future research. Am J Geriatr 
Psychiatry. 2001;9(2):113-135. 
2. 
Wolkowitz OM, Reus VI, Mellon SH. Of sound mind and body: depression, disease, and 
accelerated aging. Dialogues Clin Neurosci. 2011;13(1):25-39. 

Protocol Version: 4 
 
13 
Protocol Date: 10/12/21 
3. 
Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer 
disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 
2006;63(5):530-538. 
4. 
Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011;7(6):323-
331. 
5. 
Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF, 3rd. Late-life depression and risk of 
vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-
based cohort studies. Br J Psychiatry. 2013;202(5):329-335. 
6. 
Thomas L, Mulsant BH, Solano FX, et al. Response speed and rate of remission in primary and 
specialty care of elderly patients with depression. Am J Geriatr Psychiatry. 2002;10(5):583-591. 
7. 
Mulsant BH, Blumberger DM, Ismail Z, Rabheru K, Rapoport MJ. A systematic approach to 
pharmacotherapy for geriatric major depression. Clin Geriatr Med. 2014;30(3):517-534. 
8. 
Lenze EJ, Mulsant BH, Blumberger DM, et al. Efficacy, safety, and tolerability of augmentation 
pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, 
double-blind, placebo-controlled trial. Lancet. 2015;386(10011):2404-2412. 
9. 
Conelea CA, Philip NS, Yip AG, et al. Transcranial magnetic stimulation for treatment-resistant 
depression: Naturalistic treatment outcomes for younger versus older patients. J Affect Disord. 
2017;217:42-47. 
10. 
Kellner CH, Husain MM, Knapp RG, et al. Right Unilateral Ultrabrief Pulse ECT in Geriatric 
Depression: Phase 1 of the PRIDE Study. Am J Psychiatry. 2016;173(11):1101-1109. 
11. 
Kellner CH, Husain MM, Knapp RG, et al. A Novel Strategy for Continuation ECT in Geriatric 
Depression: Phase 2 of the PRIDE Study. Am J Psychiatry. 2016;173(11):1110-1118. 
12. 
Buchalter E, Ajam Oughli H, Lenze EJ, et al. Predicting Remission in Late-Life Major Depression: A 
Clinical Algorithm Based upon Past Treatment History. Journal of Clinical Psychiatry. In Press. 
13. 
Deng Y, McQuoid DR, Potter GG, et al. Predictors of recurrence in remitted late-life depression. 
Depress Anxiety. 2018;35(7):658-667. 
14. 
Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs. 
2009;23(8):627-647. 
15. 
Cristancho P, Lenze EJ, Dixon D, et al. Executive Function Predicts Antidepressant Treatment 
Noncompletion in Late-Life Depression. J Clin Psychiatry. 2018;79(3). 
16. 
Snyder HR. Major depressive disorder is associated with broad impairments on 
neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull. 
2013;139(1):81-132. 
17. 
Burdick DJ, Rosenblatt A, Samus QM, et al. Predictors of functional impairment in residents of 
assisted-living facilities: the Maryland Assisted Living study. J Gerontol A Biol Sci Med Sci. 
2005;60(2):258-264. 
18. 
Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135-168. 
19. 
Duncan J, Owen AM. Common regions of the human frontal lobe recruited by diverse cognitive 
demands. Trends Neurosci. 2000;23(10):475-483. 
20. 
Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. Annu Rev Neurosci. 
2001;24:167-202. 
21. 
Rajji TK, Sun Y, Zomorrodi-Moghaddam R, et al. PAS-induced potentiation of cortical-evoked 
activity in the dorsolateral prefrontal cortex. Neuropsychopharmacology. 2013;38(12):2545-
2552. 
22. 
Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry. 
1999;60 Suppl 20:9-15. 
23. 
Alexopoulos GS, Murphy CF, Gunning-Dixon FM, et al. Microstructural white matter 
abnormalities and remission of geriatric depression. Am J Psychiatry. 2008;165(2):238-244. 

Protocol Version: 4 
 
14 
Protocol Date: 10/12/21 
24. 
Galvin JE, Roe CM, Coats MA, Morris JC. Patient's rating of cognitive ability: using the AD8, a 
brief informant interview, as a self-rating tool to detect dementia. Arch Neurol. 2007;64(5):725-
730. 
25. 
Kaneriya SH, Robbins-Welty GA, Smagula SF, et al. Predictors and Moderators of Remission With 
Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-
GRey Randomized Clinical Trial. JAMA Psychiatry. 2016;73(4):329-336. 
26. 
Lowe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment 
outcomes with the patient health questionnaire-9. Med Care. 2004;42(12):1194-1201. 
27. 
Weintraub S, Dikmen SS, Heaton RK, et al. Cognition assessment using the NIH Toolbox. 
Neurology. 2013;80(11 Suppl 3):S54-64. 
28. 
Wilkinson ST, Farmer C, Ballard ED, et al. Impact of midazolam vs. saline on effect size estimates 
in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology. 
2019;44(7):1233-1238. 
29. 
Lenze EJ, Farber NB, Kharasch E, et al. Ninety-six hour ketamine infusion with co-administered 
clonidine for treatment-resistant depression: A pilot randomised controlled trial. World J Biol 
Psychiatry. 2016;17(3):230-238. 
30. 
Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal 
cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 
2014;31(4):335-343. 
31. 
Carey B. Fast-Acting Depression Drug, Newly Approved, Could Help Millions. In: New York Times; 
2019 https://www.nytimes.com/2019/03/05/health/depression-treatment-ketamine-
fda.html?fbclid=IwAR2Ezah-gY6vIfcHlXnZhw0XL1Or7ctD4B9urh0HIcgDdO2x2pT_AmgLBH4. 
32. 
Turner EH. Esketamine for treatment-resistant depression: seven concerns about efficacy and 
FDA approval. Lancet Psychiatry. 2019. 
33. 
Lapidus KA, Levitch CF, Perez AM, et al. A Randomized Controlled Trial of Intranasal Ketamine in 
Major Depressive Disorder. Biol Psychiatry. 2014. 
34. 
Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for Rapid Reduction of Suicidal Thoughts 
in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry. 
2018;175(4):327-335. 
35. 
Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on 
Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J 
Psychiatry. 2018;175(2):150-158. 
36. 
Zhang JC, Li SX, Hashimoto K. R (-)-ketamine shows greater potency and longer lasting 
antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137-141. 
37. 
Zanos P, Moaddel R, Morris PJ, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights 
into Therapeutic Mechanisms. Pharmacol Rev. 2018;70(3):621-660. 
38. 
Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of 
ketamine metabolites. Nature. 2016;533(7604):481-486. 
39. 
Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant 
without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632. 
40. 
Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-
analysis. Hum Psychopharmacol. 2015;30(3):152-163. 
41. 
Han Y, Chen J, Zou D, et al. Efficacy of ketamine in the rapid treatment of major depressive 
disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. 
Neuropsychiatr Dis Treat. 2016;12:2859-2867. 
42. 
Bryant KA, Altinay M, Finnegan N, Cromer K, Dale RM. Effects of Repeated Intravenous Ketamine 
in Treatment-Resistant Geriatric Depression: A Case Series. J Clin Psychopharmacol. 
2019;39(2):158-161. 

Protocol Version: 4 
 
15 
Protocol Date: 10/12/21 
43. 
Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral 
Antidepressant in Elderly Patients With Treatment-Resistant Depressionx2014;TRANSFORM-3. 
The American Journal of Geriatric Psychiatry. In Press. 
44. 
Lavretsky H, Roose SP. The Efficacy and Safety of Esketamine for the Treatment-Resistant 
Depression in Older Adults: Comments on TRANSFORM-3 Trial Results. American Journal of 
Geriatric Psych. In Press. 
45. 
Motov S, Mann S, Drapkin J, et al. Intravenous subdissociative-dose ketamine versus morphine 
for acute geriatric pain in the Emergency Department: A randomized controlled trial. Am J 
Emerg Med. 2019;37(2):220-227. 
46. 
Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the 
Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399-405. 
47. 
Freedman R, Brown AS, Cannon TD, et al. Can a Framework Be Established for the Safe Use of 
Ketamine? Am J Psychiatry. 2018;175(7):587-589. 
48. 
Singh I, Morgan C, Curran V, Nutt D, Schlag A, McShane R. Ketamine treatment for depression: 
opportunities for clinical innovation and ethical foresight. Lancet Psychiatry. 2017;4(5):419-426. 
49. 
Butters MA, Bhalla RK, Andreescu C, et al. Changes in neuropsychological functioning following 
treatment for late-life generalised anxiety disorder. The British Journal of Psychiatry. 
2011;199:211-218. 
50. 
Riddle M, Potter GG, McQuoid DR, Steffens DC, Beyer JL, Taylor WD. Longitudinal Cognitive 
Outcomes of Clinical Phenotypes of Late-Life Depression. The American journal of geriatric 
psychiatry : official journal of the American Association for Geriatric Psychiatry. 
2017;25(10):1123-1134. 
51. 
Pimontel MA, Rindskopf D, Rutherford BR, Brown PJ, Roose SP, Sneed JR. A Meta-Analysis of 
Executive Dysfunction and Antidepressant Treatment Response in Late-Life Depression. Am J 
Geriatr Psychiatry. 2016;24(1):31-41. 
52. 
Moda-Sava RN, Murdock MH, Parekh PK, et al. Sustained rescue of prefrontal circuit dysfunction 
by antidepressant-induced spine formation. Science. 2019;364(6436). 
53. 
Gass N, Becker R, Reinwald J, et al. Differences between ketamine's short-term and long-term 
effects on brain circuitry in depression. Transl Psychiatry. 2019;9(1):172. 
54. 
Lee Y, Syeda K, Maruschak NA, et al. A New Perspective on the Anti-Suicide Effects With 
Ketamine Treatment: A Procognitive Effect. J Clin Psychopharmacol. 2016;36(1):50-56. 
55. 
Rong C, Park C, Rosenblat JD, et al. Predictors of Response to Ketamine in Treatment Resistant 
Major Depressive Disorder and Bipolar Disorder. Int J Environ Res Public Health. 2018;15(4). 
56. 
Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO. Neurocognitive performance and serial 
intravenous subanesthetic ketamine in treatment-resistant depression. Int J 
Neuropsychopharmacol. 2014;17(11):1805-1813. 
57. 
Zheng W, Zhou YL, Liu WJ, et al. Neurocognitive performance and repeated-dose intravenous 
ketamine in major depressive disorder. J Affect Disord. 2019;246:241-247. 
58. 
Murrough JW, Burdick KE, Levitch CF, et al. Neurocognitive effects of ketamine and association 
with antidepressant response in individuals with treatment-resistant depression: a randomized 
controlled trial. Neuropsychopharmacology. 2015;40(5):1084-1090. 
59. 
Cheng WJ, Chen CH, Chen CK, et al. Similar psychotic and cognitive profile between ketamine 
dependence with persistent psychosis and schizophrenia. Schizophr Res. 2018;199:313-318. 
60. 
Ke X, Ding Y, Xu K, et al. The profile of cognitive impairments in chronic ketamine users. 
Psychiatry Res. 2018;266:124-131. 
61. 
Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration 
upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. 
Addiction. 2010;105(1):121-133. 

Protocol Version: 4 
 
16 
Protocol Date: 10/12/21 
62. 
de Souza I, Meurer Y, Tavares PM, et al. Episodic-like memory impairment induced by sub-
anaesthetic doses of ketamine. Behav Brain Res. 2019;359:165-171. 
63. 
Farber NB, Wozniak DF, Price MT, et al. Age-specific neurotoxicity in the rat associated with 
NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry. 
1995;38(12):788-796. 
64. 
Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine-induced NMDA receptor 
hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 
1999;20(2):106-118. 
65. 
Avidan MS, Maybrier HR, Abdallah AB, et al. Intraoperative ketamine for prevention of 
postoperative delirium or pain after major surgery in older adults: an international, multicentre, 
double-blind, randomised clinical trial. Lancet. 2017;390(10091):267-275. 
66. 
Hovaguimian F, Tschopp C, Beck-Schimmer B, Puhan M. Intraoperative ketamine administration 
to prevent delirium or postoperative cognitive dysfunction: A systematic review and meta-
analysis. Acta Anaesthesiol Scand. 2018;62(9):1182-1193. 
67. 
Morrison RL, Fedgchin M, Singh J, et al. Effect of intranasal esketamine on cognitive functioning 
in healthy participants: a randomized, double-blind, placebo-controlled study. 
Psychopharmacology (Berl). 2018;235(4):1107-1119. 
68. 
Kolanowski A, Mogle J, Fick DM, et al. Anticholinergic Exposure During Rehabilitation: Cognitive 
and Physical Function Outcomes in Patients with Delirium Superimposed on Dementia. Am J 
Geriatr Psychiatry. 2015;23(12):1250-1258. 
69. 
Sargent L, Nalls M, Starkweather A, et al. Shared biological pathways for frailty and cognitive 
impairment: A systematic review. Ageing Res Rev. 2018;47:149-158. 
70. 
Cristancho P, Lenard E, Lenze EJ, et al. Optimizing Outcomes of Treatment-Resistant Depression 
in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 
Participants Randomized. Am J Geriatr Psychiatry. 2019;27(10):1138-1152. 
71. 
Yoon G, Petrakis IL, Krystal JH. Association of Combined Naltrexone and Ketamine With 
Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder. 
JAMA Psychiatry. 2019;76(3):337-338. 
72. 
Williams NR, Heifets BD, Blasey C, et al. Attenuation of Antidepressant Effects of Ketamine by 
Opioid Receptor Antagonism. Am J Psychiatry. 2018;175(12):1205-1215. 
73. 
Maher DP, Chen L, Mao J. Intravenous Ketamine Infusions for Neuropathic Pain Management: A 
Promising Therapy in Need of Optimization. Anesth Analg. 2017;124(2):661-674. 
74. 
Schwartzman RJ, Alexander GM, Grothusen JR. The use of ketamine in complex regional pain 
syndrome: possible mechanisms. Expert Rev Neurother. 2011;11(5):719-734. 
75. 
Nitta R, Goyagi T, Nishikawa T. Combination of oral clonidine and intravenous low-dose 
ketamine reduces the consumption of postoperative patient-controlled analgesia morphine 
after spine surgery. Acta Anaesthesiol Taiwan. 2013;51(1):14-17. 
76. 
Pretto G, Westphal GA, Silva E. Clonidine for reduction of hemodynamic and psychological 
effects of S+ ketamine anesthesia for dressing changes in patients with major burns: an RCT. 
Burns. 2014;40(7):1300-1307. 
77. 
Tosh P, Rajan S, Puthenveettil N, Kumar L. Oral Clonidine Premedication Attenuates 
Hemodynamic Responses of Ketamine during Total Intravenous Anesthesia. Anesth Essays Res. 
2017;11(3):617-620. 
78. 
Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of 
intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol 
Psychiatry. 2018. 

Protocol Version: 4 
 
17 
Protocol Date: 10/12/21 
79. 
George D, Galvez V, Martin D, et al. Pilot Randomized Controlled Trial of Titrated Subcutaneous 
Ketamine in Older Patients with Treatment-Resistant Depression. Am J Geriatr Psychiatry. 
2017;25(11):1199-1209. 
80. 
Reynolds CF, 3rd, Frank E, Dew MA, et al. Treatment of 70(+)-year-olds with recurrent major 
depression. Excellent short-term but brittle long-term response. Am J Geriatr Psychiatry. 
1999;7(1):64-69. 
81. 
Reynolds CF, 3rd, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old 
age. New England Journal of Medicine. 2006;354(11):1130-1138. 
82. 
Reynolds CF, 3rd, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as 
maintenance therapies for recurrent major depression: a randomized controlled trial in patients 
older than 59 years. JAMA. 1999;281(1):39-45. 
83. 
Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: 
designing trials that are fit for purpose. BMJ. 2015;350:h2147. 
84. 
Rutherford BR, Wall MM, Glass A, Stewart JW. The role of patient expectancy in placebo and 
nocebo effects in antidepressant trials. J Clin Psychiatry. 2014;75(10):1040-1046. 
85. 
Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 
days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised 
placebo-controlled trial. Lancet. 2004;364(9442):1321-1328. 
86. 
Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in 
patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525-1538. 
87. 
Ford I, Norrie J. Pragmatic Trials. N Engl J Med. 2016;375(5):454-463. 
88. 
Karp JF, Buysse DJ, Houck PR, Cherry C, Kupfer DJ, Frank E. Relationship of variability in residual 
symptoms with recurrence of major depressive disorder during maintenance treatment. Am J 
Psychiatry. 2004;161(10):1877-1884. 
89. 
Lenze EJ, Ramsey A, Brown PJ, et al. Older Adults' Perspectives on Clinical Research: A Focus 
Group and Survey Study. The American journal of geriatric psychiatry : official journal of the 
American Association for Geriatric Psychiatry. 2016;24(10):893-902. 
90. 
Ramsey AT, Wetherell JL, Depp C, Dixon D, Lenze E. Feasibility and Acceptability of Smartphone 
Assessment in Older Adults with Cognitive and Emotional Difficulties. J Technol Hum Serv. 
2016;34(2):209-223. 
91. 
Kharasch ED, Neiner A, Kraus K, et al. Bioequivalence and Therapeutic Equivalence of Generic 
and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial. Clin 
Pharmacol Ther. 2019;105(5):1164-1174. 
92. 
Passmore SR, Casper E, Olgin JE, et al. Setting and motivation in the decision to participate: An 
approach to the engagement of diverse samples in mobile research. Contemp Clin Trials 
Commun. 2019;16:100428. 
93. 
Ferreira D, Kostakos V, Dey AK. AWARE: Mobile Context Instrumentation Framework. Frontiers 
in ICT. 2015;2(6). 
94. 
Bruce ML, Ten Have TR, Reynolds III CF, et al. Reducing Suicidal Ideation and Depressive 
Symptoms in Depressed Older Primary Care PatientsA Randomized Controlled Trial. JAMA. 
2004;291(9):1081-1091. 
95. 
Vidal S, Gex-Fabry M, Bancila V, et al. Efficacy and Safety of a Rapid Intravenous Injection of 
Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal 
Study. J Clin Psychopharmacol. 2018;38(6):590-597. 
96. 
Herbeck Belnap B, Schulberg HC, He F, Mazumdar S, Reynolds CF, 3rd, Rollman BL. Electronic 
protocol for suicide risk management in research participants. Journal of psychosomatic 
research. 2015;78(4):340-345. 

Protocol Version: 4 
 
18 
Protocol Date: 10/12/21 
97. 
Ryff CD. Eudaimonic well-being, inequality, and health: Recent findings and future directions. Int 
Rev Econ. 2017;64(2):159-178. 
98. 
Musich S, Wang SS, Kraemer S, Hawkins K, Wicker E. Purpose in Life and Positive Health 
Outcomes Among Older Adults. Popul Health Manag. 2018;21(2):139-147. 
99. 
Morgan CJ, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: a 
comparison of frequent, infrequent and ex-users with polydrug and non-using controls. 
Addiction. 2009;104(1):77-87. 
100. 
Zhang C, Tang WK, Liang HJ, Ungvari GS, Lin SK. Other drug use does not impact cognitive 
impairments in chronic ketamine users. Drug Alcohol Depend. 2018;186:1-8. 
101. 
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new 
comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in 
neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100. 
102. 
Cristea IA, Naudet F. US Food and Drug Administration approval of esketamine and brexanolone. 
Lancet Psychiatry. 2019. 
103. 
Weiss RD, Griffin ML, Hufford C. Craving in Hospitalized Cocaine Abusers as a Predictor of 
Outcome. The American Journal of Drug and Alcohol Abuse. 1995;21(3):289-301. 
104. 
NIMH. Notice of Information: NIMH High-Priority Areas for Research on Digital Health 
Technology to Advance Assessment, Detection, Prevention, Treatment, and Delivery of Services 
for Mental Health Conditions. 2018; https://grants.nih.gov/grants/guide/notice-files/NOT-MH-
18-031.html. 
105. 
NIMH. Opportunities and Challenges of Developing Information Technologies on Behavioral and 
Social Science Clinical Research. 2018; https://www.nimh.nih.gov/about/advisory-boards-and-
groups/namhc/reports/opportunities-and-challenges-of-developing-information-technologies-
on-behavioral-and-social-science-clinical-research.shtml. 
106. 
Gordon JA. Harnessing the Power of Technology for Mental Health. Director's Messages 2019; 
https://www.nimh.nih.gov/about/director/messages/2019/harnessing-the-power-of-
technology-for-mental-health.shtml. 
107. 
Sheffrin M, Driscoll HC, Lenze EJ, et al. Pilot study of augmentation with aripiprazole for 
incomplete response in late-life depression: getting to remission. J Clin Psychiatry. 
2009;70(2):208-213. 
108. 
Lenze E, Ances B, Schweiger J, Kharasch E, Yingling M, Farber NB. 96 Hour Infusion of Ketamine 
for Treatment Resistant Depression: Clinical and Resting State Connectivity Findings. Biological 
Psychiatry. 2017;81:S333. 
109. 
Mashour GA, Ben Abdallah A, Pryor KO, et al. Intraoperative ketamine for prevention of 
depressive symptoms after major surgery in older adults: an international, multicentre, double-
blind, randomised clinical trial. Br J Anaesth. 2018;121(5):1075-1083. 
110. 
Palanca BJA, Maybrier HR, Mickle AM, et al. Cognitive and Neurophysiological Recovery 
Following Electroconvulsive Therapy: A Study Protocol. Front Psychiatry. 2018;9:171. 
111. 
Farber NB, Foster J, Duhan NL, Olney JW. alpha 2 adrenergic agonists prevent MK-801 
neurotoxicity. Neuropsychopharmacology. 1995;12(4):347-349. 
112. 
Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C. Receptor mechanisms and circuitry 
underlying NMDA antagonist neurotoxicity. Mol Psychiatry. 2002;7(1):32-43. 
113. 
Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 
1995;52(12):998-1007. 
114. 
Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a 
randomized controlled trial. Psychol Med. 2015;45(16):3571-3580. 

Protocol Version: 4 
 
19 
Protocol Date: 10/12/21 
115. 
Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and 
implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 
2009;66(5):522-526. 
116. 
Daly EJ, Trivedi MH, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant 
Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A 
Randomized Clinical Trial. JAMA Psychiatry. 2019. 
117. 
Gao F, Miller JP, Beiser JA, Xiong C, Gordon MO. Predicting Clinical Binary Outcome Using 
Multivariate Longitudinal Data: Application to Patients with Newly Diagnosed Primary Open-
Angle Glaucoma. J Biom Biostat. 2015;6(4). 
118. 
van de Leemput IA, Wichers M, Cramer AO, et al. Critical slowing down as early warning for the 
onset and termination of depression. Proc Natl Acad Sci U S A. 2014;111(1):87-92. 
119. 
Wichers M, Groot PC. Critical slowing down as a personalized early warning signal for 
depression. . Psychotherapy and psychosomatics. 2016;85(2):114-116. 
120. 
Bringmann LF, Hamaker EL, Vigo DE, Aubert A, Borsboom D, Tuerlinckx F. Changing dynamics: 
Time-varying autoregressive models using generalized additive modeling. Psychol Methods. 
2017;22(3):409-425. 
121. 
Peng CK, Buldyrev SV, Havlin S, Simons M, Stanley HE, Goldberger AL. Mosaic organization of 
DNA nucleotides. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 1994;49(2):1685-
1689. 
122. 
Barnett I, Torous J, Staples P, Sandoval L, Keshavan M, Onnela JP. Relapse prediction in 
schizophrenia through digital phenotyping: a pilot study. Neuropsychopharmacology. 
2018;43(8):1660-1666. 
123. 
Bock C, Gumbsch T, Moor M, Rieck B, Roqueiro D, Borgwardt K. Association mapping in 
biomedical time series via statistically significant shapelet mining. Bioinformatics. 
2018;34(13):i438-i446.